Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 02, 2023

Osimertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations



Additional Info

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations
ESMO Open 2023 Mar 09;8(2)101183, LC Villaruz, X Wang, EM Bertino, L Gu, SJ Antonia, TF Burns, J Clarke, J Crawford, TL Evans, DM Friedland, GA Otterson, NE Ready, AJ Wozniak, TE Stinchcombe

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading